IPO & Public Markets

Slate Medicines appoints Mark W. Hahn, a CFO known for steering biotechs to massive acquisitions, signaling a major strategic push for its next-gen therapy.

With a historic $26.5B NASDAQ listing, SK hynix solidifies its crucial role in the AI supply chain, escalating the high-stakes race for memory dominance.

Sivers Semiconductors pushed its earnings dates. This isn't a sign of trouble; it's the steep cost of admission to Wall Street's premier league.

After a blockbuster NYSE debut, a deep dive into how manufacturer Doncasters will use $1B to pay down debt and dominate the high-tech components market.

As Cartesian Growth Corp IV launches its IPO, it's not just another blank check. It’s a test case for a new, disciplined era of strategic acquisitions.

Fresh off its IPO, EagleRock Land wipes its debt slate clean. How this strategic reset positions the company to dominate the future of energy and infrastructure.

With the $14M purchase of Envoy Technologies, BladeRanger pivots to the U.S. EV sharing market, leveraging a history of M&A to prime its new asset for an IPO.

SpaceX's record-shattering $75 billion IPO promises unprecedented access for retail investors, but a sky-high valuation and governance red flags loom large.

Canada's largest drugmaker, Apotex, launches its billion-dollar public offering, a pivotal moment for the firm and a major test for a dormant IPO market.

Amid a rebounding SPAC market, Tribeca Strategic Acquisition Corp. launches with a unique structure, aiming its $140M war chest at high-growth private companies.

AI agent developer Vida Global Inc. completes its IPO, but a volatile stock debut raises questions about its future in a booming but competitive industry.

With backing from Eli Lilly, Cabaletta Bio's $150M financing will accelerate its potentially curative cell therapies for autoimmune diseases.

LifeSci Advisors' hire of finance and IR veteran Matthew Osborne signals a strategic push amid a competitive market and a rebounding biotech IPO landscape.

The struggling footwear brand is selling its assets to become NewBird AI, a GPU provider. Is it a visionary gamble or a desperate move in the AI gold rush?

In a major strategic move, Premier Research appoints Paul Spreen as CCO, signaling a bold push to capture the rebounding biotech market.

Avory & Co. enters the crowded ETF market with AVRY, an actively managed fund shunning trends for a concentrated portfolio of high-quality stocks.

Nearly a century old, NPF Investment Advisors launches an actively managed ETF, aiming to deliver tax efficiency and long-term growth to a new generation.

As stablecoin rules tighten, a new partnership between Circle and CyberScope signals a major shift towards institutional-grade security in Web3.

As Moelis & Co. prepares to report its 2025 results, investors are watching to see if the firm capitalized on a record year for dealmaking.

As Uxin prepares to report Q3 results, all eyes are on its ambitious superstore strategy and whether it can drive profitability in a complex market.